CD8A and cancer: Beside FAS-L/FAS, the interaction of PD-L1 of cancer cells with the PD1 receptor on the surface of CD8+ T-lymphocytes is a critical reaction of the immune checkpoint resulting in functional loss of anti-cancer activity of CD8+ T-lymphocytes [36].